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This article focuses on some of the most important studies published in the year 2013 in cardiac imaging related to ischemic heart disease. Many of
the studies across the various imaging techniques addressed the prognostic impact of imaging data on outcome in patients with this disease.
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Introduction
The purpose of this review is to provide the readership of the
journal with a comprehensive overview of the clinically most rele-
vant publications in the field of cardiovascular imaging in 2013 in-
cluding echocardiography, cardiovascular magnetic resonance
(CMR), coronary computed tomography angiography (CCTA),
and radionuclide imaging. This year has witnessed important contri-
butions of cardiac imaging to the diagnosis and management of
heart failure and of valvular lesions. There has also been an increas-
ing awareness of the impact of imaging findings on the diagnosis,
prognosis, and treatment of ischaemic heart disease (IHD), which
has served to solidify the clinical value of non-invasive imaging mo-
dalities and will thus be the main focus of this manuscript. The 2013
ESC guidelines on the management of stable coronary artery
disease (CAD)1 have further emphasized the role of non-invasive
imaging to guide CAD treatment compared with previous guide-
lines, and are recommended for a more in-depth appraisal of the ap-
propriate use of these technologies.
Echocardiography
Ischaemic cardiomyopathy is a frequent cause of left ventricular dys-
synchrony. Analysis of contractile reserve has been applied to predict
the response to cardiac resynchronization therapy. In a single-centre
study of 58 guideline selected cardiac resynchronisation therapy
(CRT) candidates, this approach has now been expanded by the as-
sessment of apical rocking,2 a parameter integrating the effect of
both scar tissue and activation delays on the pattern of left ventricular
contraction. The amplitude of apical rocking during low-dose dobu-
tamine stress echo was associated with the response to CRT over a
mean follow-up of 41 months, while the changes in left ventricular
ejection fraction induced by dobutamine were not. An increase in
apical rocking, but not in left ventricular ejection fraction, was also
associated with improved long-term survival in CRT patients. Thus,
parameters more sophisticated than ejection fraction may need to
be applied for gaining an adequate functional understanding of a dys-
synchronous ventricle.
In patientswith CAD,accurate diagnosisof myocardial ischaemia is
mandatory for appropriate therapy. A decrease in myocardial perfu-
sion can be diagnosed earlier than wall motion abnormalities, which
may be a reason why single photon emission computed tomography
(SPECT) tends to be more sensitive than stress echo for detection of
CAD.3 Myocardial contrast echo, however, provides information on
both perfusion and function. Thus, a large European multicentre
study in 628 patients compared sulfur hexafluoride microbubble-
enhanced myocardial contrast echo with SPECT for the detection
of significant CAD. The trial was performed in a population exhibiting
an intermediate-to-high prevalence of CAD with all the patients re-
ceiving myocardial contrast echo, SPECT, and coronary angiography
within 1 month. Myocardial contrast echo displayed superior sensi-
tivity (Figure 1), but lower specificity for detection of CAD when
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compared with SPECT. This study strongly encourages the applica-
tion of microbubble echo contrast not only for improved wall
motion detection, but also for combining the latter with myocardial
perfusion imaging.
A prospective single-centre randomized trial performed in 2014
patients at intermediate-to-high risk for cardiac events confirmed
that the combination of myocardial perfusion imaging with wall
motion analysis improved the detection of CAD when compared
with conventional stress echo in which contrast was only used
when two continuous segments could not be visualized.4 The com-
bined approach was superior in detecting abnormalities, resulted
more often in revascularization, and was better in predicting
cardiac events.
Pharmacological stress echo is a strong predictor of events in
patients with left bundle branch block (LBBB). Doppler-derived cor-
onary flow reserve (CFR) determined during pharmacological stress
echo adds prognostic information to stress echo in patients with dia-
betes mellitus or with arterial hypertension. A large multicentre
study performed in 324 patients with known or suspected CAD
and LBBB examined whether the superior prognostic power of add-
itional Doppler measurements was also seen in patients with LBBB.5
Indeed, an abnormal CFR in the left anterior descending coronary
artery (LAD) was independently associated with a markedly
increased risk for cardiac events even in the patients on therapy
with a stress echo negative for ischaemia. This study thus emphasizes
that the assessmentof CFR in theLAD shouldbemoreoften included
in armamentarium of stress echocardiography. Along this line,
another multicentre study in 718 patients determined whether the
addition of myocardial perfusion and CFR in the LAD to wall
motion analysis increased prognostic information.6 Multivariate ana-
lysis demonstrated that risk stratification was indeed progressively
improved with the sequential addition of the parameters mentioned
above. The authors recommend this multiparametric approach for
today’s intensively treated patients arguing that the average risk for
cardiac events is so low that methods with a higher predictive sensi-
tivity than that available with standalone wall motion assessment are
required.
Appropriate use criteria decision support tools have been devel-
oped to guide physicians in selecting the appropriate imaging modal-
ity for evaluating patients with suspected CAD. A prospective
multicentre cohort study tested the impact of such a tool on clinical
practice.7 Appropriateness ratings for stress echo, myocardial perfu-
sion scintigraphy, and CCTA were provided. At the end of the test
period, the percentage of appropriate tests increased, while that of
inappropriate tests decreased, suggesting that such a tool may
improve education of physicians.
Figure 1 A 52-year-old man with significant reversible defect of the inferior wall shown by myocardial contrast echocardiography at rest (A) and
under stress (B), corresponding to an 80% stenosis of the right coronary artery on quantitative coronary angiography (C ). SPECT (D) revealed no
abnormalities. From Senior et al. 3 with permission from the journal.
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Cardiovascular magnetic
resonance
A new algorithm to improve the accuracy of detecting significant
stenoses in patients with suspected CAD uses the combination of
CMR and CCTA.8 In this single-centre study of 192 patients with
low-to-intermediate pre-test probability for CAD invasive coronary
angiography (ICA) was only performed if there was obstructive CAD
detected by coronary CTA combined with myocardial ischaemia on
CMR (Figure 2) or if CMR showed myocardial ischaemia without evi-
dence of obstructive CAD on coronary CTA. The combination with
CMR improved specificity and overall accuracy from 39 to 57% for
coronary CTA alone to 94 and 91%. Invasive coronary angiography
could be avoided in more than half of the patients based on coronary
CTA and CMR results. These patients had no cardiac events during a
follow-up of 18+6 months. Furthermore, this combined imaging
strategy provided an alternative diagnosis in 10% of patients. The
downside of this strategy is the need for substantial imaging
resources.
Several recent guidelines recommend the use of stress imaging
techniques for determining the risk of adverse events in patients
with an intermediate likelihood for obstructive CAD.1 Based on
such risk stratification, the guidelines do or do not recommend revas-
cularization. The use of CMR for the purpose of risk stratification is
supported by a 2013 study in a cohort of 815 patients. Cardiovascular
magnetic resonance demonstrated a strong association with major
adverse cardiac events when inducible ischaemia was found.9 This
was true both for those with suspected stable CAD and those with
recurrent or increasing symptoms and known CAD. Cardiovascular
magnetic resonance reclassified 91.5% of patients with intermediate
pre-test risk (65.7% to low risk, 25.8% to high risk) with correspond-
ing changes in the observed event rates (0.3 and 4.9%/year for low-
and high-risk post-test, respectively). In a meta-analysis based on
19 studies involving a total of 11 636 patients, Lipinski et al.10 found
that patients with CMR verified ischaemia had a higher incidence of
myocardial infarction [odds ratio (OR): 7.7; P, 0.0001], cardiovas-
cular death (OR: 7,0; P, 0.0001), and the combined endpoint
(OR: 6.5; P, 0.0001) compared with those with a negative study.
The presence of late gadolinium enhancement was also significantly
associated with a worse prognosis. These data put CMR with
respect to prognostication in a similar category as SPECT perfusion
and stress echocardiographic studies. The latter already have a
large data base showing that negative studies are associated with
very low event rates ,1%/year for MI and death.
Coronary computed tomography
angiography
Two 2013 papers enable us to better understand the prognostic
value of CCTA in patients with suspected CAD. In the large
Figure 2 Case example. A patient with obstructive coronary artery disease on computed tomography coronary angiography in the left anterior
descending coronaryartery (A), normal circumflex coronaryartery (B), and non-obstructive coronary artery disease in the right coronary artery (C).
Cardiovascular magnetic resonance imaging showed an adenosine stress-induced perfusion defect in the anterior and anteroseptal myocardial wall
(D, mid-ventricular short-axis orientation) and the absence of myocardial fibrosis on gadolinium late enhancement imaging (E). Invasive coronary
angiography (F) confirmed significant coronary artery disease in left anterior descending coronary artery. LV, left ventricle; RV, right ventricle. From
Groothuis et al.8
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CONFIRM registry of 20 000 patients, 347 patients died during a
median follow-up of 2.3 years.11 The best CCTA parameter for pre-
dicting mortality was the number of proximal segments with mixed
or calcified plaque and the number of proximal segments with a sten-
osis ≥50%. A proximal coronary segment containing either a mixed
or calcified plaque or a stenosis had an equivalent prognostic impact
as a 5-year increase in age or the risk of smoking. Longer follow-up
was available in a smaller study with 1584 patients followed for 5.6
years.12 The severity of CAD (categorized as normal, non-
obstructive, one-vessel, two-vessel, and three-vessel obstructive)
and the total number of plaques were the best predictors for death
and non-fatal MI. The annual event rate was nevertheless low at
1.5% even for patients with CAD and extensive plaque load (.5 seg-
ments). However, in patients without CAD the annual event ratewas
only 0.24%. These studies show that CCTA may add prognostic value
even when compared with ICA as CCTA detects non-stenotic
plaque more readily than invasive angiography.
The use of CCTA in the emergency department continued to be a
hot topic in 2013. In a retrospective study from two risk-matched
cohorts of 894 emergency department patients presenting with
chest pain, CCTA was shown to significantly reduce the overall ad-
mission rate (14 vs. 40%, P, 0.001).13 Moreover, the expected
length of stay in the emergency department was 1.6 times longer
with the standard evaluation (P, 0.001). Although there were no
differences in the rates of death and acute MI within 30 days of the
index visit, the likelihood of returning to the emergency department
within 30 days for recurrent chest pain was five times greater with the
standard evaluation (P ¼ 0.022). This study adds to the growing evi-
dence that the routine use of CCTA in the emergency department
reduces healthcare resource utilization. This important finding in
an increasingly cost conscious environment is further substantiated
by a meta-analysis including four large randomized studies looking
at a total of 3266 patients.14 All studies showed decreased length
of stay with CCTA and three of the four studies reported cost
savings. Based on these trials, it can be expected that the use of
CCTA in the emergency department will continue to grow in
order to shorten the time to diagnosis, lower cost and improve diag-
nostic precision in patients presenting with acute chest pain.
CT fractional flow reserve (CTFFR) continues to raise interest in
2013. This technique allows to determine a ‘virtual’ FFR value for a
given coronary stenosis from a standard CT coronary angiogram
using computational fluid dynamics. After the promising results of
the first pilot study, the DISCOVER-FLOW study, the enthusiasm
was somewhat tempered by the results of the larger DeFACTO
trial last year, which failed to meet the non-inferiority endpoint. A re-
cently published substudy of the DeFACTO trial assessed the diag-
nostic accuracy of intermediate lesions (defined as 30–69%
stenosis) in 407 vessels from 252 patients.15 Using invasive FFR as
the standard of reference, CTFFR demonstrated superior diagnostic
accuracy compared with CT stenosis on per-patient (AUC: 0.81 vs.
0.50, P ¼ 0.0001) and per-vessel basis (AUC: 0.79 vs. 0.53, P,
0.0001).
CT perfusion imaging (CTP) has emerged as a novel and promising
modality for detecting myocardial ischaemia. Rief et al.16 assessed the
value of CTP added to CCTA in patients in 91 consecutive patients
with coronary stents scheduled for invasive coronary angiography.
Coronary computed tomography angiography alone resulted in
22% non-diagnostic studies (metal artifacts). Adding CTP to CCTA
increased the diagnostic accuracy from 61 to 87% and the area
under the ROC curve from 0.69 to 0.82, mainly because of a
reduction in non-diagnostic examinations (gold standard: quantita-
tive coronary angiography). Hence, CTP and/or CTFFR may
become valuable assets to improve the diagnostic yield of CT in
the future in patients with equivocal, intermediate, or stented
lesions, but larger trials are needed before wide adoption of these
techniques can be advocated.
Radionuclide imaging
In 2013, the increasing availability of solid-state detector technology
(cadmium zinc telluride, CZT) for myocardial perfusion SPECT
(single-photon emission computed tomography) imaging has
offered several advantages with regard to patient comfort, radiation
safety, andduration of image acquisition. The prognostic value of such
high-speed SPECT has now also been established by Nakazato et al.17
who followed-up 1613 consecutive patients undergoing high-speed
SPECT on a CZT camera for a mean of 2.6 years. Annualized death
rates increased progressively with increasing stress total perfusion
deficit (sTPD): 0.87% or sTPD of 0%, 1.94% for sTPD of 1–4%,
3.10% for sTPD of 5–10%, and 5.33% for sTPD.10%. After adjust-
ing for several clinical baseline variables, sTPD remained a significant
predictor of all-cause mortality.
Radiation protection issues remain a hot topic in 2013 for all mo-
dalities that generate ionizing radiation and in particular for myocar-
dial perfusion SPECT. Strategies to lower radiation exposure to
patients and staff include the aforementioned CZT technology
which allows significant reduction in administered radionuclide
doses and patient-tailored protocols such as selective stress-only
imaging. Recent data from the Mount Sinai Medical Center reported
a significant reduction in administered radionuclide doses (10 746 vs.
7174 mCi), and approximately a 40% reduction in the dose equiva-
lent across all staff members after the introduction of CZT technol-
ogy and stress-only protocols in their centre.18 These changes
occurred despite a 10% increase in patient volume and were accom-
panied by a significant faster patient throughput.
Although myocardial perfusion imaging using positron emission
tomography (PET) is less frequent in Europe than in the USA, a
number of publications deserve attention. Positron emission tomog-
raphy has the unique property of being able to assess coronary vas-
cular function by measuring MBF at rest and coronary hyperaemia.
In 901 patients with chest pain or an abnormal exercise stress ECG
and yet normal PET myocardial perfusion imaging (no regional perfu-
sion defects), CFR was measured with 82Rubidium PET and coronary
artery calcium score (CACS) determined by CT.19 With increasing
CACS, CFR decreased. Over a median follow-up of 1.5 years,
annual risk-adjusted major adverse cardiac events (MACE) rates
were higher for patients with CFR ,2.0 compared with those
having a CFR ≥2.0 (5.5 vs. 1.9%/year). MACE rates also increased
for increasing calcium scores, but this increase was only borderline
statistically significant. Even for patients with a calcium score of 0,
an impaired CFR tripled the annualized adjusted MACE rate from
1.4 to 5.2%. This study underscores the mounting evidence that
CFR is an important risk factor for hard cardiac endpoints. It
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appears that at least on a short-term follow-up of 1.5 years, CFR is an
even more powerful predictor of cardiac events than CACS.
A large multicentre registry examined the prognostic value of
stress myocardial perfusion PET in patients with suspected or
known CAD.20 There were a total of 7061 patients from four
centres who had a median follow-up of 2.2 years. The risk of experi-
encing cardiac death increased with an increasing extent of myocar-
dium found to be abnormal at stress PET. Adding the information of
per cent myocardium ischaemic and per cent myocardium scarred to
a large bodyof clinical information improved model performance and
risk reclassification forcardiacdeath.The improvement in risk assess-
ment gained by adding PET data was smaller for all-cause death.
The use of myocardial perfusion PET may increase in Europe with
the introduction of new 18F-fluorinated perfusion compounds which
are currently under clinical evaluation.21 In a multicentre study of 86
patients, PET myocardial perfusion imaging with flurpiridaz F 18 was
safe and superior to SPECT MPI for image quality, interpretative cer-
tainty, and overall CAD diagnosis.
Conclusion
Imaging studies in the year 2013 underscored the value of imaging for
making the diagnosis and predicting the prognosis in patients with
suspected and established CAD. However, appropriately sized pro-
spective randomized trials to prove the impact of cardiac imaging on
patient management and clinical outcomes are still eagerly awaited.
Conflict of interest: none declared.
References
1. Montalescot G, Sechtem U, Achenbach S, Andreotti F, Arden C, Budaj A,
Bugiardini R, Crea F, Cuisset T, Di Mario C, Ferreira JR, Gersh BJ, Gitt AK,
Hulot JS, Marx N, Opie LH, Pfisterer M, Prescott E, Ruschitzka F, Sabate M,
Senior R, Taggart DP, van der Wall EE, Vrints CJ, Zamorano JL, Baumgartner H,
Bax JJ, Bueno H, Dean V, Deaton C, Erol C, Fagard R, Ferrari R, Hasdai D,
Hoes AW, Kirchhof P, Knuuti J, Kolh P, Lancellotti P, Linhart A,
Nihoyannopoulos P, Piepoli MF, Ponikowski P, Sirnes PA, Tamargo JL, Tendera M,
Torbicki A, Wijns W, Windecker S, Valgimigli M, Claeys MJ, Donner-Banzhoff N,
Frank H, Funck-Brentano C, Gaemperli O, Gonzalez-Juanatey JR, Hamilos M,
Husted S, James SK, Kervinen K, Kristensen SD, Maggioni AP, Pries AR, Romeo F,
Ryden L, Simoons ML, StegPG, Timmis A,YildirirA. 2013 ESC guidelines on the man-
agement of stable coronary artery disease: the Task Force on the management of
stable coronary artery disease of the European Society of Cardiology. Eur Heart J
2013;34:2949–3003.
2. Stankovic I, Aarones M, Smith HJ, Voros G, Kongsgaard E, Neskovic AN, Willems R,
Aakhus S, Voigt JU. Dynamic relationship of left-ventricular dyssynchrony and con-
tractile reserve in patients undergoing cardiac resynchronization therapy.EurHeart J
2013; doi:10.1093/eurheartj/eht294.
3. Senior R, Moreo A, Gaibazzi N, Agati L, Tiemann K, Shivalkar B, von Bardeleben S,
Galiuto L, Lardoux H, Trocino G, Carrio I, Le Guludec D, Sambuceti G, Becher H,
Colonna P, Ten Cate F, Bramucci E, Cohen A, Bezante G, Aggeli C, Kasprzak JD.
Comparison of sulfur hexafluoride microbubble (SonoVue)-enhanced myocardial
contrast echocardiography with gated single-photon emission computed tomog-
raphy for detection of significant coronaryartery disease: a large European multicen-
ter study. J Am Coll Cardiol 2013;62:1353–1361.
4. Porter TR, Smith LM, Wu J, Thomas D, Haas JT, Mathers DH, Williams E, Olson J,
Nalty K, Hess R, Therrien S, Xie F. Patient outcome following 2 different stress
imaging approaches: a prospective randomized comparison. J Am Coll Cardiol 2013;
61:2446–2455.
5. Cortigiani L, Rigo F, Gherardi S, Bovenzi F, Molinaro S, Picano E, Sicari R. Prognostic
implication of Doppler echocardiographic derived coronary flow reserve in patients
with left bundle branch block. Eur Heart J 2013;34:364–373.
6. Gaibazzi N, Rigo F, Lorenzoni V, Molinaro S, Bartolomucci F, Reverberi C,
Marwick TH. Comparative prediction of cardiac events by wall motion, wall
motion plus coronary flow reserve, or myocardial perfusion analysis: a multicenter
study of contrast stress echocardiography. JACC Cardiovasc Imaging 2013;6:1–12.
7. Lin FY, Dunning AM, Narula J, Shaw LJ, Gransar H, Berman DS, Min JK. Impact of an
automated multimodality point-of-order decision support tool on rates of appropri-
ate testing andclinical decisionmaking for individuals with suspected coronaryartery
disease: a prospective multicenter study. J Am Coll Cardiol 2013;62:308–316.
8. Groothuis JG, Beek AM, Brinckman SL, Meijerink MR, van den Oever ML,
Hofman MB, van Kuijk C, van Rossum AC. Combined non-invasive functional and
anatomical diagnostic work-up in clinical practice: the magnetic resonance and com-
puted tomography in suspected coronary artery disease (MARCC) study.EurHeart J
2013;34:1990–1998.
9. Shah R, Heydari B, Coelho-Filho O, Murthy VL, Abbasi S, Feng JH, Pencina M,
Neilan TG, Meadows JL, Francis S, Blankstein R, Steigner M, di Carli M,
Jerosch-Herold M, Kwong RY. Stress cardiac magnetic resonance imaging provides
effective cardiac risk reclassification in patients with known or suspected stable cor-
onary artery disease. Circulation 2013;128:605–614.
10. Lipinski MJ, McVey CM, Berger JS, Kramer CM, Salerno M. Prognostic value of stress
cardiac magnetic resonance imaging in patients with known or suspected coronary
artery disease: a systematic review and meta-analysis. J Am Coll Cardiol 2013;62:
826–838.
11. Hadamitzky M, Achenbach S, Al-Mallah M, Berman D, Budoff M, Cademartiri F,
Callister T, Chang HJ, Cheng V, Chinnaiyan K, Chow BJ, Cury R, Delago A,
Dunning A, Feuchtner G, Gomez M, Kaufmann P, Kim YJ, Leipsic J, Lin FY, Maffei E,
Min JK, Raff G, Shaw LJ, Villines TC, Hausleiter J, Investigators C. Optimized prognos-
tic score for coronary computed tomographic angiography: results from the
CONFIRM registry (COronary CT Angiography EvaluatioN For Clinical Outcomes:
An InteRnational Multicenter Registry). J Am Coll Cardiol 2013;62:468–476.
12. Hadamitzky M, Taubert S, Deseive S, Byrne RA, Martinoff S, Schomig A, Hausleiter J.
Prognostic value of coronary computed tomography angiography during 5 years of
follow-up in patients with suspected coronary artery disease. Eur Heart J 2013;34:
3277–3285.
13. Poon M, Cortegiano M, Abramowicz AJ, Hines M, Singer AJ, Henry MC, Viccellio P,
Hellinger JC, Ferraro S, Poon A, Raff GL, Voros S, Farkouh ME, Noack P. Associations
between routine coronary computed tomographic angiography and reduced un-
necessary hospital admissions, length of stay, recidivism rates, and invasive coronary
angiography in the emergency department triage of chest pain. J AmColl Cardiol 2013;
62:543–552.
14. Hulten E, Pickett C, Bittencourt MS, Villines TC, Petrillo S, Di Carli MF, Blankstein R.
Outcomes after coronary computed tomography angiography in the emergency de-
partment: a systematic review and meta-analysis of randomized, controlled trials.
J Am Coll Cardiol 2013;61:880–892.
15. Nakazato R, Park HB, Berman DS, Gransar H, Koo BK, Erglis A, Lin FY, Dunning AM,
Budoff MJ, Malpeso J, Leipsic J, Min JK. Non-invasive Fractional Flow Reserve Derived
from CT Angiography (FFRCT) for Coronary Lesions of Intermediate Stenosis
Severity: Results fromthe DeFACTOstudy.Circ Cardiovasc Imaging2013;6:881–889.
16. Rief M, Zimmermann E, Stenzel F, Martus P, Stangl K, Greupner J, Knebel F, Kranz A,
Schlattmann P, Laule M, Dewey M. Computed Tomography Angiography and Myo-
cardial Computed Tomography Perfusion in Patients With Coronary Stents: Pro-
spective Intraindividual Comparison With Conventional Coronary Angiography.
J Am Coll Cardiol 2013;62:1476–1485.
17. Nakazato R, Berman DS, Gransar H, Hyun M, Miranda-Peats R, Kite FC, Hayes SW,
Thomson LE, Friedman JD, Rozanski A, Slomka PJ. Prognostic value of quantitative
high-speed myocardial perfusion imaging. J Nucl Cardiol 2012;19:1113–1123.
18. Duvall WL, Guma KA, Kamen J, Croft LB, Parides M, George T, Henzlova MJ. Reduc-
tion in occupational and patient radiation exposure from myocardial perfusion
imaging: impactof stress-only imaging and high-efficiency SPECT camera technology.
J Nucl Med 2013;54:1251–1257.
19. Naya M, Murthy VL, Foster CR, Gaber M, Klein J, Hainer J, Dorbala S, Blankstein R, Di
Carli MF. Prognostic interplay of coronary artery calcification and underlying vascu-
lar dysfunction in patients with suspected coronary artery disease. J Am Coll Cardiol
2013;61:2098–2106.
20. Dorbala S, Di Carli MF, Beanlands RS, Merhige ME, Williams BA, Veledar E, Chow BJ,
Min JK, Pencina MJ, Berman DS, Shaw LJ. Prognostic value of stress myocardial per-
fusion positron emission tomography: results from a multicenter observational
registry. J Am Coll Cardiol 2013;61:176–184.
21. Berman DS, Maddahi J, Tamarappoo BK, Czernin J, Taillefer R, Udelson JE,
Gibson CM, Devine M, Lazewatsky J, Bhat G, Washburn D. Phase II safety and clinical
comparison with single-photon emission computed tomography myocardial perfu-
sion imaging for detection of coronary artery disease: flurpiridaz F 18 positron emis-
sion tomography. J Am Coll Cardiol 2013;61:469–477.
U. Sechtem et al.348
